Business
Ventripoint Provides Corporate Update on Market Adoption of VMS+ Whole-heart Analysis System
(TheNewswire) *** On track to Achieve Target of having 25-30 hospitals with V...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Provides Corporate Update on Market Adoption of VMS+ Whole-heart Analysis System\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n *** On track to Achieve Target of having 25-30\nhospitals with VMS+ by year end ***\n \n \n \n \n Toronto, Ontario – TheNewswire –\nNovember\n \n \n 22\n \n \n , 2021\n \n \n - Ventripoint\nDiagnostics Ltd. (\"\n \n \n Ventripoint\n \n \n \" or the \"\n \n \n Company\n \n \n \"),\n(TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF) is pleased to announce that\nit has received four more orders for the VMS+3.0 whole-heart analysis\nsystems.  These units are being manufactured at the Ventripoint\nfacility and are expected to be installed by the end of the calendar\nyear.\n \n \n \n \n “In spite of all the difficulties facing hospitals\nduring the pandemic, the Company continues to receive orders for\nVMS+3.0 units, which speaks to growing demand for rapid effective\ncardiac diagnostics to clear the backlog of patients and address the\ngrowing numbers of patients with long-COVID,” stated Dr. George\nAdams, CEO of Ventripoint.\n \n \n \n \n These four units will be installed in leading pediatric\nand adult cardiovascular centres in the UK, Canada and USA and add to\nthe existing installed base of 21 VMS+ units in Canada, United\nKingdom, Europe, USA and China.  The Company targeted to deploy 25-30\nunits by the end of 2021 and is on track to achieve this goal.\n \n \n \n \n Ventripoint expects to receive additional purchase\norders by year end but will not be able to install these units until\nearly 2022 as it takes a few weeks to schedule the installation and\ntraining in a busy echocardiography clinic.\n \n \n \n \n The Company will announce the sites as they are\ninstalled and permission is obtained to name the hospitals who have\nadopted the VMS+ approach to improved cardiac diagnostics.\n \n \n \n \n Each installation further validates VMS+ technology as\nthe alternative to cardiac MRI imaging, offering cost effective\nsolutions to ultrasound clinics everywhere - a massive market\nopportunity.\n \n \n \n \n About Ventripoint Diagnostics\nLtd.\n \n \n \n \n Ventripoint\n \n \n has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary KBR techno...